Drug intelligence / Profile preview

BP1202

Development stage: Preclinical
Lead developer: Novartis
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

BP1202 is a live biotherapeutic product developed by Aduro Biotech. It is designed to activate innate immunity within tumors. Aduro Biotech initiated an immuno-oncology collaboration with Novartis in October 2017 to utilize BP1202 in the development of bispecific antibodies. This partnership aims to combine Aduro's technology for activating innate immunity in tumors with Novartis' antibody expertise to treat cancers resistant to existing immunotherapies.

Other names: humanized anti-CD39 therapeutic antibody

Targets

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1)

Beyond the preview

Go deeper on BP1202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP1202.

Explore the full profile